Eli Lilly and Company $LLY Holdings Lowered by South Street Advisors LLC

South Street Advisors LLC decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 4.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,426 shares of the company’s stock after selling 1,264 shares during the quarter. Eli Lilly and Company accounts for about 4.3% of South Street Advisors LLC’s holdings, making the stock its 6th biggest position. South Street Advisors LLC’s holdings in Eli Lilly and Company were worth $30,549,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Maryland Capital Advisors Inc. acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $25,000. Miller Global Investments LLC acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $33,000. E Fund Management Hong Kong Co. Ltd. grew its position in shares of Eli Lilly and Company by 342.9% in the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after purchasing an additional 24 shares during the last quarter. Dorato Capital Management acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $36,000. Finally, New England Capital Financial Advisors LLC grew its position in shares of Eli Lilly and Company by 142.9% in the fourth quarter. New England Capital Financial Advisors LLC now owns 34 shares of the company’s stock valued at $37,000 after purchasing an additional 20 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on LLY. Scotiabank reiterated an “outperform” rating and issued a $1,300.00 price target on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Royal Bank Of Canada restated an “outperform” rating on shares of Eli Lilly and Company in a research report on Thursday, May 21st. TD Cowen raised their target price on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Thursday, January 29th. Cantor Fitzgerald raised their target price on shares of Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the stock an “overweight” rating in a research report on Friday, May 1st. Finally, Bank of America raised their price objective on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a “buy” rating in a report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $1,227.00.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Caremark is restoring coverage for Zepbound and adding Foundayo to drug plans, and Lilly said all three of the largest U.S. pharmacy benefit managers now cover its full obesity portfolio, improving commercial access and revenue potential. Reuters: CVS brings back coverage for Lilly’s obesity drug Zepbound
• Positive Sentiment: Lilly announced three vaccine acquisitions worth up to about $3.8 billion, signaling a broader growth strategy beyond obesity and diabetes and potentially opening a new long-term market opportunity. Reuters coverage of Lilly vaccine acquisitions
• Positive Sentiment: New clinical data presented for Foundayo, Mounjaro, and retatrutide highlighted strong efficacy in obesity and diabetes, reinforcing investor confidence in Lilly’s cardiometabolic pipeline. PR Newswire: Lilly to present new data…
• Positive Sentiment: Several analysts reiterated bullish views and higher price targets, including a BofA target increase, which supports the stock’s momentum and valuation narrative. InsiderMonkey: Eli Lilly among safe stocks
• Neutral Sentiment: Lilly’s presentation at Bernstein and upcoming conference appearances are keeping investors focused on management commentary, but these events are more about confirming the existing growth story than creating a new catalyst. Seeking Alpha transcript
• Negative Sentiment: Some commentary argues Novo Nordisk may be a better short-term value, and Lilly’s rich valuation could limit upside if growth expectations slow. Motley Fool: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $1,126.66 on Friday. The company has a market cap of $1.06 trillion, a P/E ratio of 40.02, a P/E/G ratio of 1.18 and a beta of 0.48. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,149.10. The business has a fifty day simple moving average of $952.15 and a 200-day simple moving average of $1,009.10.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities research analysts forecast that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is 24.58%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.